Virtual Tumor Board: Optimizing Personalized Care Plans for Patients With Metastatic Breast Cancer

CME/CNE : 1 + more
Start Date :  Nov 16, 2020End Date :  Nov 15, 2021

Duration :  60 Minutes

Organized by :   i3 Health

Specialties :   Nursing, Nurse Practitioner, Pharmacy and Medicine, Oncology

Fees Fee :   Starting From Free

Conference Summary

Virtual Tumor Board: Optimizing Personalized Care Plans for Patients With Metastatic Breast Cancer is organized by i3 Health.

Release Date: November 16, 2020
Expiration Date: November 15, 2021


i3 Health designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Maintenance of Certification (MOC):
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Physician Assistants:
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.0 hours of Category 1 credit for completing this program.

Nursing Continuing Professional Development:
A maximum of 1.0 contact hour may be earned by learners who successfully complete this continuing nursing education activity. This activity has been designated for 0.4 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 contact hour.

Statement of Need:
Breast cancer accounts for approximately 30% of cancer diagnoses among women in the United States and is the second-leading cause of cancer death in this population (ACS, 2020). Although many women benefit from regular screening as well as earlier and improved treatment, approximately 6% present with metastatic disease, and up to 30% with no initial lymph node involvement eventually develop metastatic disease (Siegel et al, 2020; Mortensen et al, 2018). Women with metastatic breast cancer (MBC) have a poorer prognosis than the overall population of breast cancer patients, and issues such as refractory or resistant disease, cumulative toxicities, adverse events, depression, and financial hardship are often encountered (Mortensen et al, 2018). Despite progress in understanding the pathogenesis of MBC and advances in therapy, the 5-year overall survival rate remains only 27% (Siegel et al, 2020).

Learning Objectives:
Upon completion of this activity, participants should be able to:
• Assess predictive and prognostic markers that can inform personalized care plans for patients with MBC
• Evaluate current and emerging data on therapeutic approaches for HER2-positive, hormone receptor-positive/HER2-negative, and triple-negative MBC
• Apply strategies to manage adverse events and optimize treatment outcomes of patients with MBC

• Sara M. Tolaney, MD, MPH (Chairperson)
Associate Director, Susan F. Smith Center for Women’s Cancers
Dana-Farber Cancer Institute

• Ira J. Bleiweiss, MD
Professor of Pathology
Perelman School of Medicine

• Mikel Ross, MSN, RN, AGPCNP-BC, OCN®, CBCN
Nurse Practitioner
Memorial Sloan Kettering Cancer Center

Credit Info

  • CME/CNE : 1
  • MOC : 1
  • Contact Hours : 1
Additional Info

Social Media Info :

Speaker (s)
3 Speaker(s)
Contact Us

Toll free Number

1(800) 826-2059


Chat Assistant

Live Chat